Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short term Debt (2025)

Apellis Pharmaceuticals (APLS) has 1 years of Short term Debt data on record, last reported at $93.7 million in Q4 2025.

  • For Q4 2025, Short term Debt changed N/A year-over-year to $93.7 million; the TTM value through Dec 2025 reached $93.7 million, changed N/A, while the annual FY2025 figure was $93.7 million, N/A changed from the prior year.
  • Short term Debt reached $93.7 million in Q4 2025 per APLS's latest filing, roughly flat from $93.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $93.7 million in Q4 2025 and bottomed at $93.6 million in Q3 2025.